These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21658627)

  • 1. Perspective of clinical research in follicular NHL: interaction between science and industry.
    Fine G; Horning S
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):313-21. PubMed ID: 21658627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Landgren O; Dunleavy K; Wilson WH
    J Natl Cancer Inst; 2009 Sep; 101(18):1287-8; author reply 1289-90. PubMed ID: 19687413
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituxan: the new kid on the block.
    Jonas C
    Oncol Nurs Forum; 1998 May; 25(4):669. PubMed ID: 9599347
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab: new indication. Lymphoma maintenance therapy: inadequate follow-up.
    Prescrire Int; 2007 Oct; 16(91):189. PubMed ID: 17926825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract]   [Full Text] [Related]  

  • 6. [Non-Hodgkin lymphoma becomes curable].
    Krankenpfl J; 2005; 43(1-3):40-1. PubMed ID: 15912832
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden.
    Solal-Céligny P
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S11-4. PubMed ID: 11508931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular lymphoma, survival, and rituximab: is it time to declare victory?
    Horning SJ
    J Clin Oncol; 2008 Oct; 26(28):4537-8. PubMed ID: 18662966
    [No Abstract]   [Full Text] [Related]  

  • 9. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab maintenance therapy in indolent NHL: a clinical review.
    Buske C; Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolent lymphomas: current and emerging treatment approaches.
    Maloney D; Kahl BS; Dreyling M
    Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
    J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial watch : Progress for Phase III cancer vaccines.
    Nat Rev Drug Discov; 2008 Dec; 7(12):966-7. PubMed ID: 19043443
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Tuccori M; Focosi D; Blandizzi C; Del Tacca M; Petrini M
    J Natl Cancer Inst; 2009 Sep; 101(18):1288-9; author reply 1289-90. PubMed ID: 19687414
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.